Hematology

Acute lymphoblastic leukemia accounts for nearly 25% of cancer diagnoses in children under 15 years of age.

New approach seeks to lessen resistance to cancer drugs while mitigating adverse events.

Excess medical expenses, employment disability, and a drop in production at work common in cancer survivors.

Study warns that drug reviewers don't look at long term survival of patients.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses changes in store for the care of cancer patients over the next decade.

Mass spectrometry reveals all proteins that repair damaged cancer DNA.

Genetically determined telomere length may not influence mortality.

AbbVie, Roche, and Genentech are collectively developing the drug to treat relapsed or refractory CLL patients with the 17p deletion genetic mutation.

Highest uninsured rates found in patients with testicular, stomach, and cervical cancers.

Taking over-the-counter supplements beyond the recommended amount could increase cancer risk.

Re-engineering antibodies allows them to selectively kill tumors.

Regulating PD-L1 protein that helps cancer evade immune system suggests new therapeutic approach.

Mild cognitive impairment can set in prior to the start of therapy.

Mortality gap in cancer deaths among African Americans and Caucasians may eventually disappear.

Treatment will be available for clinical trials in patients with certain types of leukemia and non-Hodgkin lymphomas later this year.

The FDA is considering approval for a liquid bendamustine hydrochloride rapid infusion product.

Longer telomeres gives cancer cells a survival advantage.

Ibrutinib found to control Waldenstrom's Macroglobulinemia in 95% of patients.

Enzyme blocker reduces growth of intestinal tumors.

Private insurers and Medicare patients can pay up to 43 times less than the uninsured.

Drug could eventually also treat prostate cancer.

Less toxic drug class combined with fasting may kill breast, lung, and colon cancer cells equally well.

Engineered protein improves survival rates in aggressive leukemia.

Compounds that prevent protein aggregation may lead to therapy for conditions such as cancer and diabetes.

Kyprolis has already been approved for patients who failed at least 2 previous therapies.

The FDA has granted priority review status to Amgen's supplemental New Drug Application for its carfilzomib (Kyprolis) cancer therapy.

Researchers believe drug will lead to ‘new paradigm' in leukemia therapy.

Scalp cooling technology seeks to ensure hair retention in most instances.

Costs have risen 120% in aggregate since 1995.

Study finds depression in African American cancer patients has gone under-recognized.